Soizic Dutoit
Nantes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells.
Journal: Cancer immunology, immunotherapy : CII
Published: September 12, 2022
Impact of automated methods for quantitative evaluation of immunostaining: Towards digital pathology.
Journal: Frontiers in oncology
Published: April 28, 2022
Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 05, 2019
Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.
Journal: Oncology reports
Published: February 16, 2017
Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?
Journal: EJNMMI research
Published: August 13, 2015
NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System.
Journal: Molecular imaging and biology
Published: December 04, 2014
Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.
Journal: International journal of cancer
Published: March 06, 2014
Biodistribution and imaging of [99mTc]-HYNIC-RGD in MDA-MB-231 and NTERA-2 cancer cell xenografts.
Journal: Nuclear medicine communications
Published: May 09, 2013
Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Journal: Apoptosis : an international journal on programmed cell death
Published: January 25, 2013
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.
Journal: Translational oncology
Published: January 02, 2013
Last Updated: 09/26/2026